These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28558966)

  • 1. Advanced Glycation End-Products Are Associated With the Presence and Severity of Paratonia in Early Stage Alzheimer Disease.
    Drenth H; Zuidema SU; Krijnen WP; Bautmans I; van der Schans C; Hobbelen H
    J Am Med Dir Assoc; 2017 Jul; 18(7):636.e7-636.e12. PubMed ID: 28558966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric Properties of the MyotonPRO in Dementia Patients with Paratonia.
    Drenth H; Zuidema SU; Krijnen WP; Bautmans I; van der Schans C; Hobbelen H
    Gerontology; 2018; 64(4):401-412. PubMed ID: 29268250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between advanced glycation end-products and functional performance in Alzheimer's disease and mixed dementia.
    Drenth H; Zuidema SU; Krijnen WP; Bautmans I; van der Schans C; Hobbelen H
    Int Psychogeriatr; 2017 Sep; 29(9):1525-1534. PubMed ID: 28539135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, incidence and risk factors of paratonia in patients with dementia: a one-year follow-up study.
    Hobbelen JS; Tan FE; Verhey FR; Koopmans RT; de Bie RA
    Int Psychogeriatr; 2011 Sep; 23(7):1051-60. PubMed ID: 21269542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive movement therapy in patients with moderate to severe paratonia; study protocol of a randomised clinical trial (ISRCTN43069940).
    Hobbelen JS; Verhey FR; Bor JH; de Bie RA; Koopmans RT
    BMC Geriatr; 2007 Dec; 7():30. PubMed ID: 18093298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of inflammaging and advanced glycation end products on paratonia in patients with dementia.
    Drenth H; Zuidema S; Bautmans I; Hobbelen H
    Exp Gerontol; 2020 Dec; 142():111125. PubMed ID: 33132147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosing paratonia in the demented elderly: reliability and validity of the Paratonia Assessment Instrument (PAI).
    Hobbelen JS; Koopmans RT; Verhey FR; Habraken KM; de Bie RA
    Int Psychogeriatr; 2008 Aug; 20(4):840-52. PubMed ID: 18177542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Paratonia on Fine and Gross Motor Function in Older Adults With Mild and Moderate Dementia.
    Van Deun B; Van Den Noortgate N; Van Bladel A; Palmans T; Cambier D
    Alzheimer Dis Assoc Disord; 2019; 33(1):54-61. PubMed ID: 30371515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducible Measurements of Muscle Characteristics Using the MyotonPRO Device: Comparison Between Individuals With and Without Paratonia.
    Van Deun B; Hobbelen JSM; Cagnie B; Van Eetvelde B; Van Den Noortgate N; Cambier D
    J Geriatr Phys Ther; 2018; 41(4):194-203. PubMed ID: 28005829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and impact of paratonia in Alzheimer disease in a multiracial sample.
    Vahia I; Cohen CI; Prehogan A; Memon Z
    Am J Geriatr Psychiatry; 2007 Apr; 15(4):351-3. PubMed ID: 17384318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive movement therapy in severe paratonia: a multicenter randomized clinical trial.
    Hobbelen JH; Tan FE; Verhey FR; Koopmans RT; de Bie RA
    Int Psychogeriatr; 2012 May; 24(5):834-44. PubMed ID: 22185768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paratonia: a Delphi procedure for consensus definition.
    Hobbelen JS; Koopmans RT; Verhey FR; Van Peppen RP; de Bie RA
    J Geriatr Phys Ther; 2006; 29(2):50-6. PubMed ID: 16914066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing Paratonia in Persons With Dementia: Short-term Effects of Supporting Cushions and Harmonic Techniques.
    Van Deun B; Van Den Noortgate N; Van Bladel A; De Weerdt K; Cambier D
    J Am Med Dir Assoc; 2019 Dec; 20(12):1521-1528. PubMed ID: 31227470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Advanced Glycation End Products on the Progression of Alzheimer's Disease.
    Chou PS; Wu MN; Yang CC; Shen CT; Yang YH
    J Alzheimers Dis; 2019; 72(1):191-197. PubMed ID: 31561370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paratonia in Dementia: A Systematic Review.
    Drenth H; Zuidema S; Bautmans I; Marinelli L; Kleiner G; Hobbelen H
    J Alzheimers Dis; 2020; 78(4):1615-1637. PubMed ID: 33185600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes.
    Di Pino A; Currenti W; Urbano F; Scicali R; Piro S; Purrello F; Rabuazzo AM
    Nutr Metab Cardiovasc Dis; 2017 Nov; 27(11):978-984. PubMed ID: 28958695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitory paratonia and frontal lobe functioning.
    Beversdorf DQ; Heilman KM
    Neurology; 1998 Oct; 51(4):968-71. PubMed ID: 9781514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Comorbidity in Patients With Young-Onset Alzheimer Disease Compared With Late-Onset: A Comparative Cohort Study.
    Gerritsen AA; Bakker C; Verhey FR; de Vugt ME; Melis RJ; Koopmans RT;
    J Am Med Dir Assoc; 2016 Apr; 17(4):318-23. PubMed ID: 26778489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma clusterin and the risk of Alzheimer disease.
    Schrijvers EM; Koudstaal PJ; Hofman A; Breteler MM
    JAMA; 2011 Apr; 305(13):1322-6. PubMed ID: 21467285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.